Google
APLS 株価分析 — APELLIS PHARMACEUTICALS INC (Healthcare >> Biotechnology)
APLS に関するよくある質問
APLSのPER（株価収益率）は？
APELLIS PHARMACEUTICALS INC（APLS）は現在PER 22.41倍で取引されています。
APLSのROE（自己資本利益率）は？
APELLIS PHARMACEUTICALS INCのROEは32.12%です。
APLSの配当利回りは？
APELLIS PHARMACEUTICALS INCの配当利回りは0.00%です。
APLSの品質スコア（Quality Score）は？
当社のAIはAPLSの総合財務品質を100点中77点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
APLSは今が買い時ですか？
当社AIのタイミングスコアは100点中0点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
APLSはどのセクターに属しますか？
APELLIS PHARMACEUTICALS INCはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
APLS AI Analysis Summary
Our AI summary for APLS: APELLIS PHARMACEUTICALS INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 22.41, ROE of 32.12%, a dividend yield of 0.00%. Its financial Quality Score stands at 77/100 — mid-range fundamentals relative to the market. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 3.40
Price
0.34
(11.27%)
Day Change
|
|
|---|
APLS, ファンダメンタルスコアはgood ( ファンダメンタル = 77) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
平均ROEが低い
ROAがROEに比べて低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
55% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
2397
|
| Magic Formula Rank by ROE |
2397
|
| Magic Formula Rank by ROIC |
635
|
| Price | 3.40 |
| PBV / Sector |
12.66 / 5.20
|
| Earning Per Share | 0.09 |
| PE / Sector |
22.41 / 19.97
|
| PEG or PE/Growth / Sector |
-0.33 / 1.22
|
| Average 1M Daily Value |
439.627775000000
|
| Average 1W Daily Value |
421.271800000000
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:29 |
| Symbol | APLS |
| Name | APELLIS PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 128.02 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 5,252.71 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 100 Fifth Avenue, Waltham, MA, United States, 02451
Phone: 617 977 5700
Website: https://apellis.com
Employees: 733
Sector: Healthcare >> Biotechnology
Description: Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts. As of May 14, 2026, Apellis Pharmaceuticals, Inc. operates as a subsidiary of Biogen Inc.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
